IR-Med

IR-Med, Inc. is engaged in the designing and developing devices utilizing spectrographic usability medical devices based on the combination of Infra-Red (IR) and Artificial Intelligence (AI) technologies. The company is headquartered in New York City, New York and currently employs 3 full-time employees. The company went IPO on 2001-07-18. PressureSafe, the Company’s first product based on this platform, is a handheld device designed to revolutionize the assessment of pressure injuries (PI) affecting skin and underlying tissue. The firm is developing its technology through its subsidiary and is utilizing Infra-Red-light spectroscopy (IR) combined with an artificial intelligence (AI) technology platform to develop non-invasive devices for various medical indications, by assessing various biomarkers and molecules in the blood and in human tissue in real-time. The second product candidate, DiaSafe, which is under development, is a non-invasive, user-friendly device which is designed to address medical needs by offering assessment of Diabetic Foot Ulcer (DFU) before skin breakage.